Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression)

被引:130
作者
Appelhof, BC
Huyser, J
Verweij, M
Brouwer, JP
van Dyck, R
Fliers, E
Hoogendijk, WJG
Tijssen, JGP
Wiersinga, WM
Schene, AH
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, NL-1100 DE Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, NL-1100 DE Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1100 DE Amsterdam, Netherlands
[4] Free Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands
关键词
major depression; relapse; prediction; dexamethasone/corticotropin-releasing hormone test; outpatients;
D O I
10.1016/j.biopsych.2005.09.008
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Knowledge of pathogenic mechanisms and predictors of relapse in major depressive disorder is still limited. Hypothalamic-pituitary-adrenocortical (HPA) axis dysregulation is thought to be related to the development and course of depression. Methods: We investigated whether dexamethasone/corticotropin-releasinig hormone (DEX/CRH) test parameters were related to the occurrence of relapse in 45 outpatients with clinically remitted major depression. The DEX/CRH test was administered before and after 8 weeks of antidepressant treatment. Results: Posttreatment maximal adrenocorticotropic hormone (ACTH) and maximal cortisol levels, as well as delta ACTH and delta cortisol levels, were significantly higher (all p < .05) among patients who relapsed (n = 22) compared with patients in whom no relapse occurred (n = 23). Higher posttreatment maximal cortisol response on the DEX/CRH test was associated with shorter "relapse-free survival" (p = 05). Conclusions: In outpatients with clinically remitted major depression., higher posttreatment maximal cortisol levels on the DEX/CRH test were associated with relapse of major depression.
引用
收藏
页码:696 / 701
页数:6
相关论文
共 27 条
[1]   Triiodothyronine addition to paroxetine in the treatment of major depressive disorder [J].
Appelhof, BC ;
Brouwer, JP ;
van Dyck, R ;
Fliers, E ;
Hoogendijk, WJG ;
Huyser, J ;
Schene, AH ;
Tijssen, JGP ;
Wiersinga, WM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (12) :6271-6276
[2]  
BECK AT, 1976, PHARMACOPSYCHIATRY, V7, P51
[3]   An open label trial of C-1073 (mifepristone) for psychotic major depression [J].
Belanoff, JK ;
Rothschild, AJ ;
Cassidy, F ;
DeBattista, C ;
Baulieu, EE ;
Schold, C ;
Schatzberg, AF .
BIOLOGICAL PSYCHIATRY, 2002, 52 (05) :386-392
[4]   Rapid reversal of psychotic depression using mifepristone [J].
Belanoff, JK ;
Flores, BH ;
Kalezhan, M ;
Sund, B ;
Schatzberg, AF .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (05) :516-521
[5]   Thyroid and adrenal axis in major depression: a controlled study in outpatients [J].
Brouwer, JP ;
Appelhof, BC ;
Hoogendijk, WJG ;
Huyser, J ;
Endert, E ;
Zuketto, C ;
Schene, AH ;
Tijssen, JGP ;
Van Dyck, R ;
Wiersinga, WM ;
Fliers, E .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (02) :185-191
[6]   Comparability of telephone and in-person structured clinical interview for DSM-III-R (SCID) diagnoses [J].
Cacciola, JS ;
Alterman, AI ;
Rutherford, MJ ;
McKay, JR ;
May, DJ .
ASSESSMENT, 1999, 6 (03) :235-242
[7]   The impact of treatment-resistant depression on health care utilization and costs [J].
Crown, WH ;
Finkelstein, S ;
Berndt, ER ;
Ling, D ;
Poret, AW ;
Rush, AJ ;
Russell, JM .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (11) :963-971
[8]  
First M.B., 2002, Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P)
[9]   Adrenal steroid secretion and major depression in 8- to 16-year-olds, III. Influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression [J].
Goodyer, IM ;
Herbert, J ;
Altham, PME .
PSYCHOLOGICAL MEDICINE, 1998, 28 (02) :265-273
[10]  
HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]